Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates

Virology Journal

Volumn 9, Issue , 2012, Pages

  Jaspe, Rossana C ^a   Sulbarán, Yoneira F ^a   Sulbarán, Maria Z ^a   Loureiro, Carmen L ^a   Rangel, Hector R ^a   Pujol, Flor H ^a  

^a Instituto Venezolano de Investigaciones Cientificas Centro de Microbiologia y Biologia Celular   (Venezuela)

Author keywords

Core; HCV; Mutation; NS5B

Indexed keywords

AMINO ACID; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; ASIA; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UNINDEXED SEQUENCE; VENEZUELA; VIRUS ISOLATION;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION RATE; PHYLOGENY; VENEZUELA; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84866495878     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-214     Document Type: Article

References (46)

1. World health organization report June 2011, fact sheet N°164, http://www.who.int/mediacentre/factsheets/fs164/en/
2. Prevalence of hepatitis C virus infection in Venezuela assessed by a synthetic peptide-based immunoassay. Aguilar MS, Cosson C, Loureiro CL, Devesa M, Martínez J, Villegas L, Flores J, Ludert JE, Noya O, Liprandi F, Pujol FH, Alarcán de Noya B, Ann Trop Med Parasitol 2001 95 187 195 10.1080/00034980120042944 11299125 (Pubitemid 32304216)
3. Prevalence of hepatitis C virus in urban and rural populations of northeast brazil-pilot study. Silva L, Paraná R, Mota E, Cotrim HP, Bonnec-McCurtey ML, Vitvitinsky L, Pádua A, Trepo C, Lyra L, Arq Gastroenterol 1995 32 168 171 8734852
4. Prevalence of antibodies to hepatitis a, C, and E viruses in different groups in French Guiana. Talarmin A, Kazanji M, Cardoso T, Pouliquen J-F, Sankale-Suzanon J, Sarthou JL, J Med Virol 1997 52 430 435 10.1002/(SICI)1096- 9071(199708)52:4<430::AID-JMV15>3.0.CO;2-K 9260693 (Pubitemid 27356192)
5. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Hung CH, Lee CM, Lu SN, Expert Rev Anti Infect Ther 2011 9 5 525 533 10.1586/eri.11.33 21609264
6. Replacement of hepatitis C virus genotype 1b by genotype 2 over a 10 year period in Venezuela. Pujol FH, Loureiro CL, J Clin Gastroenterol 2007 41 518 520 10.1097/01.mcg.0000248010.55149.ce 17450037 (Pubitemid 46642542)
7. Genetic history of hepatitis C virus in Venezuela: high diversity and long time of evolution of HCV genotype 2. Sulbarán MZ, Di Lello FA, Sulbarán Y, Cosson C, Loureiro CL, Rangel HR, Cantaloube JF, Campos RH, Moratorio G, Cristina J, Pujol FH, PLoS One 2010 5 12 14315 10.1371/journal. pone.0014315 21179440
8. A new standard of care for the treatment of chronic HCV infection. Hofmann WP, Zeuzem S, Nat Rev Gastroenterol Hepatol 2011 8 5 257 264 21468124
9. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S, J Hepatol 2011 55 1 69 75 10.1016/j.jhep.2010.10.032 21145856
10. Hepatitis C virus genotypes and quasispecies. Davis GL, Am J Med 1999 107 21S 26S 10.1016/S0002-9343(99)00376-9 10653451
11. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC, J Gen Virol 1994 75 Pt 5 1053 1061 8176367 (Pubitemid 24143150)
12. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H, J Med Virol 2009 81 6 1032 1039 10.1002/jmv.21473 19382270
13. The complicated relationships of amino acid substitution in HCV core region and IL28Bgenotype influencing hepatocarcinogenesis. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H, Hepatology In press
14. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Fishman SL, Factor SH, Balestrieri C, Fan X, Dibisceglie AM, Desai SM, Benson G, Branch AD, Clin Cancer Res 2009 15 9 3205 3213 10.1158/1078-0432.CCR-08-2418 19383824
15. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N, Cancer Sci 2009 100 12 2465 2468 10.1111/j.1349-7006.2009. 01338.x 20175782
16. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H, J Med Virol 2010 82 1 41 48 10.1002/jmv.21629 19950230
17. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O, Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O, J Hepatol 2010 52 1 72 78 Erratum in: J Hepatol 2010, 52(4):620 10.1016/j.jhep.2009.10.001 19910070
18. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H, Intervirology 2012 55 3 231 241 10.1159/000328327 21734353
19. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H, Intervirology 2005 48 6 372 380 10.1159/000086064 16024941 (Pubitemid 41003622)
20. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y, J Hepatol 2010 52 5 672 680 10.1016/j.jhep.2009.10.034 20346532
21. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E, Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N, J Med Virol 2011 83 3 419 427 10.1002/jmv.21975 21264862
22. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N, J Viral Hepat 2011 18 4 117 e125 10.1111/j.1365-2893.2010.01379.x 20955493
23. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. Kurbanov F, Tanaka Y, Matsuura K, Sugauchi F, Elkady A, Khan A, Hasegawa I, Ohno T, Tokuda H, Mizokami M, J Infect Dis 2010 201 1663 1671 10.1086/652500 20420509
24. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H, Intervirology 2009 52 6 301 309 10.1159/000235909 19729953
25. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H, J Med Virol 2010 82 4 575 582 10.1002/jmv.21741 20166188
26. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H, Intervirology 2012 55 6 417 425 10.1159/000323526 21325786
27. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H, Liver Int 2010 30 4 554 559 10.1111/j.1478-3231.2009.02164.x 19951380
28. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. Sumida Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Yoshida N, Yasui K, Itoh Y, Okanoue T, Yoshikawa T, J Gastroenterol Hepatol 2011 26 5 836 842 10.1111/j.1440-1746.2010.06568.x 21054524
29. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM, J Infect Dis 2008 197 2 283 291 10.1086/524846 18177246 (Pubitemid 351263449)
30. Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation. Jhaveri R, Qiang G, Diehl AM, J Infect Dis 2009 200 11 1781 1788 10.1086/648094 19852667
31. A review on an update of NS5B polymerase hepatitis C virus inhibitors. Varshney J, Sharma PK, Sharma A, Eur Rev Med Pharmacol Sci 2012 16 5 667 671 22774409
32. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M, J Gastroenterol Hepatol 2005 20 9 1401 1409 10.1111/j.1440-1746.2005.04024.x 16105128 (Pubitemid 43960839)
33. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S, J Hepatol 2005 43 4 623 629 10.1016/j.jhep.2005.05.032 16098627 (Pubitemid 41253229)
34. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA, J Biol Chem 2003 278 49 49164 49170 10.1074/jbc.M305041200 12966103
35. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues. Dutartre H, Bussetta C, Boretto J, Canard B, Antimicrob Agents Chemother 2006 50 12 4161 4169 10.1128/AAC.00433-06 17000745 (Pubitemid 44865161)
36. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, Bard J, Chopra R, Krishnamurthy G, Mansour T, O'Connell J, Antimicrob Agents Chemother 2008 52 9 3327 3338 10.1128/AAC.00238-08 18559648
37. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I, Antimicrob Agents Chemother 2009 53 5 2129 2132 10.1128/AAC.01598-08 19273674
38. Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C. Margeridon-Thermet S, Shafer RW, Viruses 2010 2 12 2696 2739 10.3390/v2122696 21243082
39. Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors. Furui Y, Hoshi Y, Murata K, Ito K, Suzuki K, Uchida S, Satake M, Mizokami M, Tadokoro K, J Med Virol 2011 83 11 1924 1929 10.1002/jmv.22216 21915867
40. Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients. Castilho MC, Martins AN, Horbach IS, Perez Rde M, Figueiredo FA, Pinto Pde T, Nabuco LC, de Lima DB, Tanuri A, Porto LC, Ferreira Júnior Oda C, Mem Inst Oswaldo Cruz 2011 106 8 968 975 22241118
41. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. Hang JQ, Yang Y, Harris SF, Leveque V, Whittington HJ, Rajyaguru S, Ao-Ieong G, McCown MF, Wong A, Giannetti AM, Le Pogam S, Talamás F, Cammack N, Nájera I, Klumpp K, J Biol Chem 2009 284 23 15517 15529 10.1074/jbc.M808889200 19246450
42. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Nájera I, Antimicrob Chemother 2008 61 6 1205 1216 10.1093/jac/dkn085 (Pubitemid 351753583)
43. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. Plaza Z, Soriano V, Gonzalez Mdel M, Di Lello FA, Macias J, Labarga P, Pineda JA, Poveda E, J Antimicrob Chemother 2011 66 12 2838 2842 10.1093/jac/dkr385 21954459
44. Evidence for separation of HCV subtype 1a into two distinct clades. Pickett BE, Striker R, Lefkowitz EJ, J Viral Hepat 2011 18 9 608 618 10.1111/j.1365-2893.2010.01342.x 20565573
45. Epidemic history of hepatitis C virus in brazil. Lampe E, Espirito-Santo MP, Martins RM, Bello G, Infect Genet Evol 2010 10 7 886 895 10.1016/j.meegid.2010.05.010 20663735
46. Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs. Peres-da-Silva A, Almeida AJ, Lampe E, Mem Inst Oswaldo Cruz 2012 107 2 254 261 22415266